about
Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer.18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread.Clinical Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer.A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer PatientsSerum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian CancerMathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian CancerALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitorsPET/CT for Evaluation of Ovarian CancerEuropium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign SourcesVirtual clinical trials identify effective combination therapies in ovarian cancerBehavior of FDG-avid supradiaphragmatic lymph nodes in PET/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective studyOpen Source Infrastructure for Health Care Data Integration and Machine Learning Analyses
P50
Q38705569-58CEFC7F-C67C-4677-AC9C-455116D69752Q38751114-84B06727-FD01-4087-8B4F-57C4D8ADBCB2Q40785031-C94546C5-66CC-4F81-B6B3-1624A65AC878Q44774158-701407B7-5B46-418B-9162-1C0FD3867A8FQ51130755-372DAB49-5127-44C3-ADA8-79015D065945Q51312595-3FE0AD29-E9A3-4A40-916E-6F632D046C57Q51748262-E841601D-3A4F-4497-A158-70A995609F8CQ52989572-A431CC95-E605-44BA-96CB-E95392E9CF5CQ53096948-3B8AED5A-315D-40A5-B730-731D16F090B9Q53163950-7FA815D4-737C-49C8-B760-AE1E365CF7DDQ53822175-B9A2DE5A-3FDB-47E0-B031-C7D1A51FE99BQ59571732-46199AC4-6971-4A55-BACF-95A5BAFA2322Q84656894-EDF09D62-B3AA-41EB-99F6-A659DE8006C4Q88697370-38CD1323-BB55-485C-981B-B756B229C4E3Q90604434-DF80C2FA-FF1C-4B0B-A2A5-E6FEA0C276B1Q90827365-415316C9-AAD8-4973-BF92-EC0983C2B8C5Q90974565-336EF346-E1F4-4741-9952-FE87F3EC6F5DQ91854766-8985AF24-2DA5-4E16-9191-EDE5B729F82BQ92379326-F97C7DE6-AEE1-48C4-A47B-82971248C838Q92900002-67FFE6F6-D3BB-458E-B6E0-BE92AD4F0C1B
P50
description
researcher ORCID ID = 0000-0002-0854-7225
@en
name
Johanna Hynninen
@ast
Johanna Hynninen
@en
Johanna Hynninen
@es
Johanna Hynninen
@nl
type
label
Johanna Hynninen
@ast
Johanna Hynninen
@en
Johanna Hynninen
@es
Johanna Hynninen
@nl
prefLabel
Johanna Hynninen
@ast
Johanna Hynninen
@en
Johanna Hynninen
@es
Johanna Hynninen
@nl
P21
P31
P496
0000-0002-0854-7225